U.S. STOCKS ON THE MOVE-Paramount Global, First Horizon, Soligenix
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, Moderna, Shopify
Soligenix up on positive results from compatibility study of cancer therapy
Brief: Soligenix Announces Positive Clinical Results From Compatibility Study Of Hybryte™ In The Treatment Of Cutaneous T-Cell Lymphoma
Brief: Soligenix Says Board Increased Size Of Board From Five To Six Members
Brief: Soligenix Announces Appointment Of Timothy Coté To Its Board Of Directors
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini
U.S. STOCKS ON THE MOVE-Minerva Neurosciences, Midwest Holding, Global Payments
U.S. STOCKS ON THE MOVE-Norwegian Cruise Line, Marker Therapeutics, KBR
Soligenix up on pact for blood vessel inflammation treatment
Brief: Soligenix Enters Into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease
Brief: Soligenix Submits Type A Meeting Request To U.S. FDA
Soligenix falls as cancer therapy review by FDA delayed
Brief: Soligenix Provides Regulatory Update On Hybryte
Brief: Soligenix Granted Extension Of Deadline To Regain Compliance With Shareholders' Equity Requirement
Brief: Soligenix Receives Usan Approval For "Hypericin Sodium" As Nonproprietary Name For Novel Active Ingredient In Hybryte And Sgx302
Brief: Soligenix Announces Scheduling Of Type A Meeting With U.S. FDA For Hybryte New Drug Application
Brief: Soligenix Files For Offering Up To $12.0 Mln Of Shares Of Common Stock
Brief: Soligenix Reports 2022 Loss Per Share Of $4.81